

Ⅲ．引用文献 71

- cyclophosphamide. *Eur J Gynaecol Oncol* 1997 ; 18 : 343-8.
- 3) McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med* 1996 ; 334 : 1-6.
 - 4) Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer : three-year results. *J Natl Cancer Inst* 2000 ; 92 : 699-708.
 - 5) Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, et al. Chemotherapy in advanced ovarian cancer : four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. *Br J Cancer* 1998 ; 78 : 1479-87.
 - 6) Ozols RF, Bundy BN, Greer BE, Fowley JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : A Gynecologic Oncology Group Study. *J Clin Oncol* 2003 ; 21 : 3194-200.
 - 7) du Bois A, Lueck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. *J Natl Cancer Inst* 2003 ; 9 : 1320-9.
 - 8) du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. *J Natl Cancer Inst* 2003 ; 95 : 1320-9.
 - 9) 安田允, 木村英三, 落合和徳, 多田聖郎, 宇田川康博, 青木大輔, 他, 卵巣癌に対する Paclitaxel と Carboplatin の併用化学療法のパilot-Phase I Study (JKTB)-推奨用量について-. *癌と化学療法* 2001 ; 28 : 493-8.
 - 10) Kuzuya K, Ishikawa H, Nakanishi T, Kikkawa F, Nawa A, Fujimura H, et al. Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer : a phase I modified continual reassessment method study. *Int J Clin Oncol* 2001 ; 6 : 271-8.
 - 11) 波多江正紀, 大西義孝, 中村俊昭, 中島久良, 森山伸吾, 高尾直大, 他, 卵巣癌に対するパクリタキセル(TAX)とカルボプラチン(CBDCA)のPhase I Study 会議録. *日本癌治療学会誌* 1998 ; 33 : 274.
 - 12) Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer : high-dose versus low-dose and long versus short infusion. *J Clin Oncol* 1994 ; 12 : 2654-66.
 - 13) Young RC, Bell JG, Lage J. A randomized phase III trial of carboplatin (AUC7.5) and paclitaxel 175mg/m² q21 days x3 courses versus the same regimen x6 courses, in patients with selected stage Ic and II (A,B,C) and selected IA and IB ovarian cancer. 2002 GOG Statistical Report.
 - 14) Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol) /carboplatin in early stage ovarian cancer. *Semin Oncol* 2000 ; 27 : 8-10.
 - 15) Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial : two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. *J Natl Cancer Inst* 2003 ; 95 : 105-12.
 - 16) Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International collaborative ovarian neoplasm trial 1 : a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. *J Natl Cancer Inst* 2003 ; 95 : 125-32.
 - 17) Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma : european organisation for research and treatment of cancer - adjuvant chemotherapy in ovarian neoplasm trial. *J Natl Cancer Inst* 2003 ; 95 : 113-25.
 - 18) Murphy D, Crowther D, Rennison J, Prendiville J, Ranson M, Lind M, et al. A randomized dose intensity study in ovarian carcinoma comparing chemotherapy given at four week

72 第4章 資料集

- intervals for six cycles with half dose chemotherapy given for twelve cycles. *Ann Oncol* 1993 ; 4 : 377-83.
- 19) Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. *Lancet* 1992 ; 340 : 329-33.
 - 20) Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish gynecology cancer trials group. *J Clin Oncol* 1996 ; 14 : 2113-9
 - 21) McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer. A gynecologic oncology group study. *J Clin Oncol* 1995 ; 13 : 1589-99.
 - 22) Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, et al. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer : a randomized study of the Gruppo Oncologico Nord-Ovest. *J Clin Oncol* 1996 ; 14 : 351-6.
 - 23) Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, et al. Dose-effect study of carboplatin in ovarian cancer : A Danish Ovarian Cancer Group Study. *J Clin Oncol* 1997 ; 15 : 193-8.
 - 24) Colombo N, Maggioni A, Vignali M, Parma G, Mangioni C. Options for primary chemotherapy in advanced ovarian cancer : the European perspective. *Gynecol Oncol* 1994 ; 55 : S108-13.
 - 25) Gore M, Mainwaring P, A' Hern R, MacFarlane V, Slevin M, Harper P, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. *J Clin Oncol* 1998 ; 16 : 2426-34.
 - 26) Thigpen JT. Dose-intensity in ovarian carcinoma : hold, enough? *J Clin Oncol* 1997 ; 15 : 1291-3.
- C. 寛解導入・補助オプション
- 1) Vasey PA. Survival and longer-term toxicity results of the SCOTROC study : docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). *Proc ASCO* 2002 ; 21 : 202a (804).
 - 2) Wu CH, Yang CH, Lee JN, Hsu SC, Tsai EM. Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. *Int J Gynecol Cancer* 2001 ; 11 : 295-9.
 - 3) Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer : a gynecologic oncology group study. *J Clin Oncol* 2000 ; 18 : 106-15.
 - 4) ICON Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer : the ICON3 randomized trial. *Lancet* 2002 ; 360 : 505-15.
 - 5) Gershenson DM, Morris M, Burke TW, Levenback C, Kavanagh JJ, Fromm GL, et al. : Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. *Gynecol Oncol* 1995 ; 58 : 349-55.
 - 6) 中村俊昭, 大西義孝, 山本文子, 前田隆嗣, 波多江正紀. 上皮性卵巣癌 Stage III・IV 期に対する JP (Carboplatin・Cisplatin) 併用療法の長期予後. *日本癌治療学会誌* 2000 ; 35 : 555
 - 7) Sugiyama T, Yakushiji M, Kamura T, Ikeda M, Umesaki N, Hasegawa K, et al. Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer. *Oncology* 2002 ; 63 : 16-22
- D. 留意事項
- 1) Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, et al. Sequences of taxol and cisplatin : a phase I and pharmacologic study. *J Clin Oncol* 1991 ; 9 : 1692-703.

Ⅲ. 引用文献 73

- 2) Calvert AH, Egorin MJ. Carboplatin dosing formulae : gender bias and the use of creatinine-based methodologies. *Eur J Cancer* 2002 ; 38 : 11-6.
- 3) Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976 ; 16 : 31-41.
- 4) Jelliffe RW, Letter : Creatinine clearance : bedside estimate. *Ann Intern Med* 1973 ; 79 : 604-5.
- 5) Dupont JS, Soignet SL, Spriggs DR. General principles of chemotherapy. In : Barakat RR, Bevers MW, Gershenson DM, Hoskins WJ, editors. *Handbook of Gynecologic Oncology*. 2nd ed. London. Martin Dunitz 2002 ; 47-76.
- 6) Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldboom EP, Burroughs JN, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. *J Clin Oncol* 1992 ; 10 : 520-8.
- 7) Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, et al. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. *European Lung Cancer Working Party. Eur J Cancer* 1999 ; 35 : 1314-9.
- 8) Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. *J Clin Oncol* 1999 ; 17 : 1141.
- 9) Peereboom DM, Donehower RC, Eisenhauer EA, McGuire WP, Onetto N, Hubbard JL, et al. Successful re-treatment with taxol after major hypersensitivity reactions. *J Clin Oncol* 1993 ; 11 : 885-90.
- 10) Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF, et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. *Ann Oncol* 1997 ; 8 : 611-4.

E. 支持療法

- 1) 日本癌治療学会臨床試験委員会 : G-CSF 適正使用ガイドライン. *Int J Clinical Oncol* 2001 ; 6 (Suppl) : 1-24.
- 2) American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors : evidence-based, clinical practice guidelines. *J Clin Oncol* 1994 ; 12 : 2471-508.
- 3) Update of recommendations for the use of hematopoietic colony-stimulating factors : evidence-based clinical practice guidelines. American Society of Clinical Oncology. *J Clin Oncol* 1996 ; 14 : 1957-60.
- 4) Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ. Use of hematopoietic colony-stimulating factors : Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. *J Clin Oncol* 1999 ; 17 : 3676-81.
- 5) Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. *Ann Intern Med* 1966 ; 64 : 328-40.
- 6) Gavia JM, Garrido SM, Root RK. Clinical use of granulocyte colony-stimulating factor in infectious diseases. *Curr Clin Top Infect Dis* 2001 ; 21 : 302-22.
- 7) Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors : evidence-based, clinical practice guidelines. *J Clin Oncol* 2000 ; 18 : 3558-85.
- 8) Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. *J Clin Oncol* 1997 ; 15 : 2981-95.
- 9) Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. *J Clin Oncol* 1998 ; 16 : 3179-90.
- 10) Bokemeyer C, Kuczyk MA, Kohne H, Einsele H, Kynast B, Schmoll HJ. Hematopoietic growth factors and treatment of testicular cancer : biological interactions, routine use and dose-intensive chemotherapy. *Ann Hematol* 1996 ; 72 : 1-9.
- 11) Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations

74 第4章 資料集

for the use of antiemetics : evidence-based, clinical practice guidelines. *J Clin Oncol* 1999 ; 17 : 2971-94.

F. 術前化学療法

- 1) Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. *Gynecol Oncol* 1990 ; 37 : 327-31.
- 2) 清水敬生, 荷見勝彦. FIGO III・IV期悪性卵巣腫瘍に対する治療成績—Neoadjuvant 化学療法は有用か?—. *日産婦誌* 1993 ; 45 : 1007-14.
- 3) Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. *Gynecol Oncol* 1994 ; 53 : 33-7.
- 4) Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. *Eur J Gynaecol Oncol* 1996 ; 17 : 393-6.
- 5) Zylberberg B, Dormont D, Jankiewicz S, Darai E, Bretel JJ, Poncelet C, et al. Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer. *Eur J Gynaecol Oncol* 2001 ; 22 : 40-5.
- 6) Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIc ovarian carcinoma. *Cancer* 2001 ; 92 : 2585-91.
- 7) Vrscaj MU, S.Rakar. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma : A retrospective case-control study. *Eur J Gynaecol Oncol* 2002 ; 23 : 405-10.
- 8) Ushijima K, Ota S, Komai K, Matsuo G, Motoshima S, Honda S et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. *Int Surg* 2002 ; 87 : 185-90.
- 9) Fruehauf JP, Yu IR, Parker R. In vitro drug response and biomaker profiles for ovarian cancer specimens obtained at initial debulking or after neoadjuvant chemotherapy (EORTC 55971) . *Proc ASCO* 2002 ; 21 : 91b (2177) .

G. 維持科学療法

- 1) Young RC, Brady MF, Nieberg RM, Long HJ, Mayer AR, Lentz SS, et al. Adjuvant treatment for early ovarian cancer : a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin—a gynecologic oncology group study. *J Clin Oncol* 2003 ; 2 : 4350-5.
- 2) Trope C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. *Ann Oncol* 2000 ; 11 : 281-8.
- 3) Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, et al. Adjuvant treatment for early epithelial ovarian cancer : results of two randomized clinical trials comparing cisplatin to no further treatment or chronic phosphate (32P) . *GICOG. Ann Oncol* 1995 ; 6 : 887-93.
- 4) Mannel R, Kohn EC, Michael H. A randomized phase III trial of iv carboplatin (AUC6) and paclitaxel 175mg/mm q21days x3 courses plus low dose paclitaxel 40mg/mm/wk versus iv carboplatin (AUC6) and paclitaxel 175mg/mm q21days x3 courses plus observation in patients with early stage ovarian carcinoma. *GOG protocol175. Gynecologic Oncology Group statistical report* 2004 ; 402.
- 5) Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD , et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy : A Southwest Oncology Group and Gynecologic Oncology Group trial. *J Clin Oncol* 2003 ; 21 : 2460-5.
- 6) Barakat RR, Almadrones L, Venkatraman ES, Aghajanian C, Brown C, Shapiro F, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II - IV epithelial ovarian cancer following negative surgical assessment. *Gynecol*

Ⅲ. 引用文献 75

- Oncol 1998 ; 69 : 17-22.
- 7) Cure H, Battista C, Guastalla J, Fabbro M, Tubiana-Mathieu N, Bourgeois H, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC) : Preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc ASCO 2001 ; 204a.
 - 8) Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992 ; 45 : 284-9.
 - 9) Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen JE, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer : A Danish ovarian study group trial (DACOVA). Gynecol Oncol 1993 ; 49 : 30-6.
 - 10) Boruta DM, Fowler WC, Gehrig PA, Boggess JF, Walton LA, VanLe L. Weekly paclitaxel infusion as consolidation therapy in ovarian cancer. Proc ASCO 2002 ; 21 : 215a (856).
 - 11) Chiara S, Lionetto R, Campora E, Oliva C, Merlini L, Bruzzi P, et al. Long-term prognosis following macroscopic complete response at second-look laparotomy in advanced ovarian cancer patients treated with platinum-based chemotherapy. The Gruppo Oncologico Nord Ovest. Eur J Cancer 1995 ; 31 : 296-301.

H. 腹腔内化学療法

- 1) Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982 ; 97 : 845-51.
- 2) Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996 ; 335 : 1950-5.
- 3) Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma : an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001 ; 19 : 1001-7.
- 4) Armstrong DK, Bundy BN, Baergen R, Lele SB, Copeland LJ, Walker J, et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC) : a Gynecologic Oncology Group Trial (GOG 172). Proc ASCO 2002 ; 21 : 201a (803).
- 5) Rubin SC, Hoskins WJ, Markman M, Hakes T, Lewis JL Jr. Long-term access to the peritoneal cavity in ovarian cancer patients. Gynecol Oncol 1989 ; 33 : 46-8.
- 6) Adachi S, Noda T, Ito K, Kiyozuka Y, Itani Y, Shintani M, et al. Complications associated with CDDP intraperitoneal chemotherapy. Asia-Oceania J Obstet Gynaecol 1994 ; 20 : 7-12.

I. その他

- 1) Shinozuka T, Miyamoto T, Muramatsu T, Hirasawa T, Murakami M, Makino T, et al. High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma : long term results for 105 patients. Cancer 1999 ; 85 : 1555-64.
- 2) Benedetti-Panici P, Greggi S, Scambia G, Salerno MG, Menichella G, Pierelli L, et al. High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Ann Med 1995 ; 27 : 133-8.
- 3) Thigpen JT. Dose-intensity in ovarian carcinoma : hold, enough? J Clin Oncol 1997 ; 15 : 1291-3.
- 4) Aghajanian C, Fennelly D, Shapiro F, Waltzman R, Almadrones L, O'Flaherty C, et al. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.

76 第4章 資料集

J Clin Oncol 1998 ; 16 : 1852-60.

V. 境界悪性腫瘍(上皮性)の治療—フローチャートとその解説—

- 1) Trope C, Kaern J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993 ; 51 : 236-43.
- 2) Kaern J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993 ; 71 : 1810-20.
- 3) Barnhill DR, Kurman RJ, Brady MF, Omura GA, Yordan E, Given FT, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential : A Gynecologic Oncology Group study. J Clin Oncol 1995 ; 13 : 2752-6.
- 4) Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002 ; 86 : 34-7.
- 5) Leake JF, Rader JS, Woodruff JD, Rosenshein NB. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1991 ; 42 : 124-30.
- 6) Fort MG, Pierce VK, Saigo PE, Hoskins WJ, Lewis JL Jr. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1989 ; 32 : 269-72.
- 7) Sutton GP, Bundy BN, Omura GA, Yordan EL, Beecham JB, Bonfiglio T. Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). Gynecol Oncol 1991 ; 41 : 230-3.
- 8) Barakat RR, Benjamin I, Lewis JL Jr, Saigo PE, Curtin JP, Hoskins WJ. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 1995 ; 59 : 390-3.

VI. 初回治療後のフォローアップ

- 1) Ovarian Cancer Guideline (Version 1.2002). National Comprehensive Cancer Network.
- 2) 河野一郎, 藤原恵一, 鈴木幸子. 再発卵巣癌の診断と治療. 癌の臨床 1997 ; 43 : 1363-9.
- 3) Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. J Epidemiol Biostat 2001 ; 6 : 107-38.
- 4) Niloff JM, Bast RC Jr, Schaetzel EM, Knapp RC. Predictive value of CA125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985 ; 151 : 981-6.
- 5) Makar AP, Kristensen GB, Bormer OP, Trope CG. Is serum CA125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol 1993 ; 49 : 3-7.
- 6) Meier W, Baumgartner L, Stieber P, Hasholzner U, Fateh-Maghadam A. CA125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res 1997 ; 17 : 3019-20.
- 7) 津村宜彦, 櫻木範明, 田中俊誠, 藤本征一郎. 原発性上皮性卵巣癌再燃における血中 CA-125 値の正常範囲内変動の意義について. 産婦人科治療 1990 ; 61 : 854-9.
- 8) Gard GB, Houghton CR. An assessment of the value of serum CA125 measurement in the management of epithelial ovarian carcinoma. Gynecol Oncol 1994 ; 53 : 283-9.
- 9) 市村友季, 金岡靖, 梅咲直彦, 辰田一郎, 川村直樹, 本田謙一, 他. 再発の診断および予後の予知因子としての CA125 値の検討. 産婦進歩 1995 ; 47 : 591-3.
- 10) Sugiyama T, Nishida T, Komai K, Nishimura H, Yakushiji M, Nishimura H. Comparison of CA125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer. Int J Gynecol Obstet 1996 ; 54 : 251-6.
- 11) 三好端, 薬師寺道明. 各種腫瘍マーカーのカット・オフ値. Oncol Chemother 1990 ; 5 : 301-5

VII. 再発卵巣癌の治療—フローチャートとその解説—

- 1) Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin

Ⅲ. 引用文献 77

- Oncol 1991 ; 9 : 389-93.
- 2) Harries M, Gore M. Part II : Chemotherapy for epithelial ovarian cancer - treatment of recurrent disease. *Lancet Oncology* 2002 ; 3 : 537-45.
 - 3) Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. *Gynecol Oncol* 2001 ; 83 : 128-34.
 - 4) Rose PG, Fusco N, Fluellen L, Rodrigues M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. *J Clin Oncol* 1998 ; 16 : 1494-7.
 - 5) The ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer : the ICON4/AGO-OVAR-2.2 trial. *Lancet* 2003 ; 361 : 2099-106.
 - 6) Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma : application toward a dynamic disease state model of ovarian cancer. *J Clin Oncol* 2002 ; 20 : 1238-47.
 - 7) Ghamande S, Lele S, Marchetti D, Baker T, Odunsi K. Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. *Int J Gynecol Cancer* 2003 ; 13 : 142-7.
 - 8) Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. *J Clin Oncol* 1997 ; 15 : 187-92.
 - 9) 野田起一郎, 池田正典, 工藤隆一, 西谷巖, 矢嶋聰, 田中憲一, 他. Paclitaxel (BMS-181339) の卵巣癌患者に対する臨床第Ⅱ相試験(3時間点滴静注). *癌と化学療法* 1996 ; 23 : 317-25.
 - 10) Alberola V, Rosell R, Gonzalez-Larriba JL, Molina F, Ayala F, Garcia-Conde J, et al. Single agent taxol, 3-hour infusion, in untreated advanced non-small cell lung cancer. *Ann Oncol* 1995 ; 6 : 49-52.
 - 11) Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, et al. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. *Gynecol Oncol* 2003 ; 88 : 51-7.
 - 12) Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes E, Steger M, Nelson-Taylor T, et al. Docetaxel for patients with paclitaxel-resistant mullarian carcinoma. *J Clin Oncol* 2000 ; 18 : 2733-9.
 - 13) Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma : A Gynecologic Oncology Group Study. *Gynecol Oncol* 2003 ; 88 : 130-5.
 - 14) Katsumata N, Tsunematsu R, Tanaka K, Terashima Y, Ogita S, Hoshiai H, et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer : A Japanese cooperative study. *Ann Oncol* 2000 ; 11 : 1531-6.
 - 15) Matsumoto K, Katsumata N, Andoh M, Yamanaka Y, Kitagawa R, Shimizu C, et al. Efficacy of irinotecan in patients with platinum and taxane-resistant ovarian cancer. *Proc ASCO* 2003 ; 22 : 464 (1863).
 - 16) Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, et al. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. *J Clin Oncol* 2003 ; 21 : 291-7.
 - 17) Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma. a Gynecologic Oncology Group Study. *J Clin Oncol* 1998 ; 16 : 405-10.
 - 18) Harries M, Gore M. Chemotherapy for recurrent ovarian cancer. Part II : Chemotherapy for epithelial ovarian cancer - treatment of recurrent disease. *The Lancet Oncology* 2002 ; 3 : 537-45.
 - 19) Markman M. Second-line treatment of ovarian cancer with single-agent gemcitabine. *Semin Oncol* 2002 ; 29 : 9-10.
 - 20) Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ. Weekly cisplatin and oral etoposide as

78 第4章 資料集

- treatment for relapsed epithelial ovarian cancer. *Ann Oncol* 2001 ; 12 : 1705-9.
- 21) van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G, et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. *Br J Cancer* 2002 ; 86 : 19-25.
 - 22) 葛谷和夫. 卵巣がん委員会: 新規研究プロトコル案について-卵巣がん研究 JGOG3015 (特定研究) プロトコルについて- 第19回婦人科がん化学療法共同研究会記録集(別冊). 2002 ; 37-44.
 - 23) Maenpaa JU, Ala-Fossi SL, Kivinen ST, Pohto MK, Kaar KK, Jekunen AP. Docetaxel and irinotecan in the second-line treatment of ovarian cancer : final results of a phase II study. *Proc ASCO* 2002 ; 21 : 224a (894) .
 - 24) Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC. Treatment preferences in recurrent ovarian cancer. *Gynecol Oncol* 2002 ; 86 : 200-11.

第3章 胚細胞腫瘍

- 1) Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. *CA Cancer J Clin* 1997 ; 47 : 5-27.
- 2) Williams SD. Current management of ovarian germ cell tumors. *Oncology* 1994 ; 8 : 53-60.
- 3) Albrektsen G, Heuch I, Kvale G. Full-term pregnancies and incidence of ovarian cancer of stromal and germ cell origin : A Norwegian prospective study. *Br J Cancer* 1997 ; 75 : 767-70.
- 4) O'Conner DM, Norris HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. *Int J Gynecol Pathol* 1994 ; 13 : 283-9.
- 5) Norris HJ, Zirken HJ, Benson WL. Immature (malignant) teratoma of the ovary : a clinical and pathologic study of 58 cases. *Cancer* 1976 ; 37 : 2359-72.
- 6) Kurman RJ, Norris HJ. Malignant germ cell tumors of the ovary. *Hum Pathol* 1977 ; 8 : 551-64.
- 7) Talerman A. Management of germ cell tumors of the ovary ; in Kurman RJ (ed) : *Blaustein's Pathology of the Female Genital Tract*. New York, NY, Springer-Verlag 1987 ; 659-721.
- 8) Williams SD. Ovarian germ cell tumors : an update. *Semin Oncol* 1998 ; 25 : 407-13.
- 9) Gershenson DM. Managements of early ovarian cancer : germ cell and sex cord-stromal tumors. *Gynecol Oncol* 1994 ; 55 : S62-S72.
- 10) Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni, et al. Surgical management of malignant ovarian germ-cell tumors : 10 Year's experience of 129 patients. *Obstet Gynecol* 1995 ; 86 : 367-72.
- 11) 高松愛, 上坊敏子, 岩谷弘明, 立岡和弘, 脇田邦夫, 秦宏樹, 他. 卵巣悪性胚細胞腫瘍の臨床病理的検討. *日癌治誌* 1996 ; 31 : 334-41.
- 12) National Cancer Institute, PDQ (R) . med News. Treatment statement for Health Professional. Ovarian germ cell tumors (PDQ), 2002. <https://www.meb.uni-bonn.de/cancer.gov/CDR0000062935.html>.
- 13) Williams SD, Blessing JA, DiSaia PJ, Major FJ, Ball HG 3rd, Liao SY. Second-look laparotomy in ovarian germ cell tumors : the Gynecologic Oncology Group experience. *Gynecol Oncol* 1994 ; 52 : 287-91.
- 14) Gershenson DM. The obsolescence of second-look laparotomy in the management of malignant ovarian germ cell tumors. *Gynecol Oncol* 1994 ; 52 : 283-5.
- 15) Smith JP, Rutledge F. Advances in chemotherapy for gynecologic cancer. *Cancer* 1975 ; 36 : 669-74.
- 16) Slayton RE, Hreshchyshyn MM, Silverberg SC, Shingleton HM, Park RC, DiSalia PJ, et al. Treatment of malignant ovarian germ cell tumors : response to vincristine, dactinomycin, and cyclophosphamide (preliminary report) . *Cancer* 1978 ; 42 : 390-8.
- 17) Gershenson DM, Del Junco G, Herson J, Rutledge FN. Endodermal sinus tumor of the ovary : the M. D. Anderson experience. *Obstet Gynecol* 1983 ; 61 : 194-202.

Ⅲ. 引用文献 79

- 18) Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT, Blessing JA. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary : A Gynecologic Oncology Group Study (a final report) . *Cancer* 1985 ; 56 : 243-8.
- 19) Gershenson DM, Copeland LJ, Kavanagh JJ, Cangir A, Del Junco G, Saul PB, et al. Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin, and cyclophosphamide. *Cancer* 1985 ; 56 : 2756-61.
- 20) Gershenson DM, del Junco G, Silva EG, Copeland LJ, Wharton JT, Rutledge FN. Immature teratoma of the ovary. *Obstet Gynecol* 1986 ; 68 : 624-9.
- 21) Einhorn LH, Donohue J. Cis - diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. *Ann Intern Med* 1977 ; 87 : 293-8.
- 22) Taylor MH, Depetrillo AD, Turner R. Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary. *Cancer* 1985 ; 56 : 1341-9.
- 23) Williams SD, Blessing JA, Moore DH, Homesley HD, Adcock L. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors : A trial of Gynecologic Oncology Group. *Ann Intern Med* 1989 ; 111 : 22-7.
- 24) Kumar L, Bhargawa VL, Kumar S. Cisplatin, vinblastine and bleomycin in advanced and relapsed germ cell tumours of ovary. *Asia Oceania J Obstet Gynecol* 1993 ; 19 : 133-40.
- 25) Williams SD, Birch R, Einhorn L, Irwin L, Greco A, Loehrer PJ. Treatment of disseminated germ - cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. *New Engl J Med* 1987 ; 316 : 1435-40.
- 26) Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. *J Clin Oncol* 1990 ; 8 : 715-20.
- 27) Williams SD, Blessing JA, Hatch KD, Homesley HD. Chemotherapy of advanced dysgerminoma : trials of the Gynecologic Oncology Group. *J Clin Oncol* 1991 ; 9 : 1950 - 5.
- 28) Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin : a trial of the Gynecologic Oncology Group. *J Clin Oncol* 1994 ; 12 : 701-6.
- 29) de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, et al. Importance of bleomycin in combination chemotherapy for good - prognosis testicular nonseminoma : a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. *J Clin Oncol* 1997 ; 15 : 1837-43.
- 30) Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors : a multiinstitutional study. *J Clin Oncol* 1993 ; 11 : 598-606.
- 31) Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer : ifosfamide and cisplatin plus either vinblastine or etoposide. [published erratum appears in *Ann Intern Med* 1988 ; 109 : 846] . *Ann Intern Med* 1988 ; 109 : 540-6.
- 32) McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin - containing chemotherapy as first - line salvage therapy in germ cell tumors : response and survival. *J Clin Oncol* 1997 ; 15 : 2559-63.
- 33) Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PJ, Einhorn LH, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. *Ann Intern Med* 1992 ; 117 : 124-8.
- 34) Linkesch W, Greinix HT, Hocker P, Krainer M, Wagner A. Longterm follow up of phase I / II trial of ultra - high carboplatin, VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. *Proceeding of the 12th Am Soc Clin Oncol* 1993 ; 232 (abstr 717) .
- 35) Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High - dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors : treatment results and prognostic factors for survival and toxicity. *J Clin Oncol* 1996 ; 14 : 1098-105.

80 第4章 資料集

- 36) Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. *J Clin Oncol* 2000 ; 18 : 2413-18.
- 37) Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem - cell rescue in patients with relapsed or refractory germ cell cancer. *J Clin Oncol* 2001 ; 19 : 81-8.
- 38) Nicosia SV, Matus - Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. *Cancer* 1985 ; 55 : 2364-72.
- 39) Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. *J Clin Oncol* 1988 ; 6 : 270-5.
- 40) Segelov E, Campbell J, Ng M, Tattersall M, Rome R, Free K, et al. Cisplatin - based chemotherapy for ovarian germ cell malignancies : The Australian experience. *J Clin Oncol* 1994 ; 12 : 378-84.
- 41) Mitchell PL, Al-Nasiri N, A'Hern R, Fisher C, Horwich A, Pinkerton CR, et al. Treatment of nondysgerminomatous ovarian germ cell tumors : An analysis of 69 cases. *Cancer* 1999 ; 85 : 2232-44.
- 42) Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. *J Clin Oncol* 1999 ; 17 : 2670-5.
- 43) Kanazawa K, Suzuki T, Sakumoto K. Treatment of malignant ovarian germ cell tumors with preservation of fertility : reproductive performance after persistent remission. *Am J Clin Oncol* 2000 ; 23 : 244-8.
- 44) Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. *Cancer* 2000 ; 89 : 391-8.
- 45) Tangir J, Zeltermann D, Ma W, Schwartz PE. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. *Obstet Gynecol* 2003 ; 101 : 251-57.
- 46) Nichols CR, Breeden ES, Loehrer PJ, Williams SD, Einhorn LH. Secondary leukemia associated with a conventional dose of etoposide : review of serial germ cell tumor protocols. *J Natl cancer Inst* 1993 ; 85 : 36-40.
- 47) Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ cell tumours. *Lancet* 1991 ; 338 : 359-63.
- 48) Jobo T, Hirano S, Hata H, Iwaya H, Sato R, Kuramoto H. Secondary acute leukemia following chemotherapy for ovarian cancer : report of five cases. *Int J Clin Oncol* 1999 ; 4 : 175-9.

和文索引

あ

アクチノマイシン D 52, 57
 悪性転化を伴う成熟嚢胞性奇形腫 48
 悪性胚細胞腫瘍 48
 悪性卵巣腫瘍 11

い

イホスファミド 34, 54, 57
 イリノテカン 28, 34, 45
 インフォームドコンセント 22
 維持化学療法 24, 36, 37

え

エトポシド 34, 45, 52, 54, 56, 57
 エトポシド投与 56
 エビルピシン 28, 34

か

カルチノイド 48
 カルボプラチン 25, 27, 28, 30, 34, 45, 57
 外診 43
 寛解 24
 患者因子 15
 患側付属器摘出術 23, 41, 50
 寛解導入化学療法 24
 緩和医療 46

き

基本術式 16
 機能温存手術 50
 奇形腫 48
 急性過敏反応 31
 急性白血病 56
 胸部 X 線 43
 境界悪性腫瘍 41
 境界悪性胚細胞腫瘍 48

け

経膈超音波 43
 経腹超音波 43

こ

甲状腺腫性カルチノイド 48

後障害 56
 後腹膜リンパ節 (骨盤・傍大動脈) 郭清術 17, 23
 後腹膜リンパ節生検 23, 41
 骨シンチグラム 43
 骨髓異形成 56
 骨髓抑制 32
 混合型胚細胞腫瘍 47, 48

さ

再発卵巣癌 44
 再発率 53
 残存腫瘍径 15

し

シクロホスファミド 25, 28, 34, 52, 56, 57
 シスプラチン 25, 27, 28, 34, 52, 57
 ジェムシタビン 45, 57
 子宮摘出術 17, 50
 支持療法 32
 試験開腹 16
 試験的化学療法 24
 腫瘍因子 15
 腫瘍減量手術 16, 46
 腫瘍マーカー 43, 49
 腫瘍マーカー値 14
 受診間隔 42
 絨毛癌 47, 48
 術後化学療法 24, 35
 術後補助化学療法 22
 術前化学療法 24, 35
 術中迅速組織診断 41
 術中迅速病理検査 14, 50
 初回化学療法 44
 消化器症状 34

せ

セカンドルック手術 20, 51
 制吐剤 34
 精巣腫瘍 52
 精巣胚細胞腫瘍 52
 洗浄細胞診 17
 前投薬 31

そ

組織学的分化度 13
 奏効率 53, 54
 造血幹細胞移植 40

た

タキサン製剤 25
 ダブルプラチナ (JP) 療法 29
 多胎芽腫 48
 大網全切除術 17
 大網切除術 17, 50
 大網全切除術 17,
 大網部分切除術 17, 23
 大量化学療法 54
 対側卵巣生検 50
 胎芽性癌 47, 48
 胎児性癌 48

ち

治療因子 15
 地固め療法 24, 36, 37
 虫垂切除術 17
 超大量化学療法 40

て・と

テラルピシン 28
 トポテカン 37
 ドキソルビシン 25, 28, 34, 57
 ドセタキセル 28, 34, 45, 57
 毒性 27

な

内視鏡手術 21
 内胚葉洞腫瘍 48
 内診 43

に

二次化学療法 44
 二次的腫瘍縮小術 51
 二次発癌 56
 妊孕性 56
 妊孕性温存 22, 49, 50

ね・は

粘液性腺癌 15

82 索引

パクリタキセル 25, 27, 28, 30,
34, 45, 54, 57
胚細胞腫瘍 47
発熱性好中球減少症 33

ひ

ピンクリスチン 52, 57
ピンブラスチン 52, 54, 57
被膜破綻 13

ふ

フォローアップ 42
プレオマイシン 34, 52, 57
プラチナ製剤 25, 27, 52
プラチナ製剤感受性 44
プラチナ製剤抵抗性 44
腹腔鏡 43
腹腔内化学療法 38
腹腔細胞診 17, 23

腹腔内生検 41

へ・ほ

米国臨床腫瘍学会 33
保存手術術式 22
補助化学療法 24
放射線感受性 47
放射線療法 46

み

未熟奇形腫 47, 48, 50, 52
未分化胚細胞腫 47, 48, 50, 52

む

無増悪期間 35
無病期間 19
無病生存率 40, 52, 53

め

メソトレキセート 57
明細胞腺癌 15, 26

も・ゆ・よ

問診 43
有害反応 38
予後因子 15

ら

ランダム化比較試験 23
卵黄嚢腫瘍 47, 48
卵巣機能障害 56

り

リンパ節転移頻度 18
両側付属器摘出術 17, 50
臨床試験 46

欧文索引

A

adjuvant chemotherapy 24
AFP 47, 49
AGO 27
AGO-GINECO OVAR7 37
area under the concentration-time
curve 25
ASCO 32, 33
AUC 25

B・C

BEP療法 49, 52, 55, 56
CA125 43
Calvert 30
CAP療法 25, 28, 37
cCR 26
cisplatin-based chemotherapy
54
CJ療法 28

clinical complete response 26
colony stimulating factor 32
complete response 12
conservative surgery 22
consolidation therapy 24, 36
CP療法 25, 26, 28
CR 12
CT 43
CSF 32, 33
cytoreduction 16
cytoreductive surgery 16

D

debulking 16
debulking surgery 12
DFI 19
DFS 37
disease-free interval 19
disease-free survival 37

DJ療法 28, 29
dose-intensive chemotherapy
27
dose intensity 40

E

ECOG 38, 39
EORTC 19
EORTC55875 37
EORTC55971 35
EORTC-ACTION 26
EP療法 52

F

febrile neutropenia 33
FIGO 11, 13
first-line salvage chemotherapy
54
FN 33

- G**
- Ga シンチグラム 43
 G-CSF 32
 germ cell tumor 47
 GOG 13, 38, 39
 GOG114 39
 GOG172 38, 39
 GOG175 36
 GOG178 37
 GOG111 26
 GOG152 19
 GOG157 26
 GOG158 27
 GOG47 25
- H**
- hCG 47, 49
 high-dose chemotherapy 37, 40, 54
- I**
- ICON1 26
 IDS 13, 16, 19, 35
 interval debulking surgery 13, 16, 19
 intraperitoneal chemotherapy 38
 ip療法 38
 IRB 46
 IVP 43
- J**
- JCOG study 35
 JP療法 28, 29
- L・M**
- LDH 47, 49
 maintenance chemotherapy 24, 36
 maximum debulking 15, 35
 median survival time 39
 MRI 43
 MST 39
- N**
- NAC 35
 National Comprehensive Cancer Network 34
 NC 12
 NCCN 22, 34, 35, 42, 43
 neoadjuvant chemotherapy 16, 24, 35
 NIH 20, 21, 22, 43
 NIH consensus statement 21, 42
 no change 12
- O**
- optimal 12
 optimal debulking 19
 optimal surgery 15
 OS 19, 26, 37
 OV-10 26
 overall survival 19, 26, 37
- P**
- partial response 12
 pathological complete response 26
 PBSCT 37, 40
 pCR 26
 PD 12
 PFI 19
 PFS 19, 26, 35
 platinum-free interval 44
 PR 12
 primary debulking surgery 16, 41
 progression-free interval 19
 progression-free survival 19, 26
 progressive disease 12
 PtFI 44
 PVB療法 49, 52, 55, 56
- Q・R**
- QOL 35, 46
 remission 24
- remission induction therapy 24
- S**
- salvage chemotherapy 13, 24, 45
 SCOTROC 29
 SDS 13, 16, 19, 20, 35
 second-line salvage chemotherapy 54
 second look operation 16, 20
 secondary debulking surgery 13, 16, 19
 SEER 11
 seminoma 47
 SLO 16, 20, 51
 staging laparotomy 12, 16, 41
 suboptimal 12
 suboptimal debulking 19
 surgical staging 15
 SWOG 38, 39
 SWOG8501 39
 SWOG9701 37
 SWOG-S0009 35
- T**
- TIP療法 54, 55
 TJ療法 25, 29, 30, 31
 TP療法 25, 26
- V**
- VAC療法 49, 52, 55, 56
 VeIP療法 54, 55
 VIP療法 54, 55
- W**
- weekly-TJ療法 28, 29
 WHO 13
 WHO分類 47
- 数字**
- 5-フルオロウラシル 57
 5年生存率 11

卵巢がん治療ガイドライン 2004年版

定価(本体1,800円+税)

2004年10月20日 第1版第1刷発行

2005年3月1日 第2刷発行

編集 日本婦人科腫瘍学会

発行者 川井弘光

発行所 金原出版株式会社

〒113-8687 東京都文京区湯島2-31-14

電話 編集 ————— (03)3811-7162

営業 ————— (03)3811-7184

FAX ————— (03)3813-0288

振替口座 ————— 00120-4-151494

<http://www.kanehara-shuppan.co.jp/>


©2004

検印省略

Printed in Japan

ISBN4-307-30085-8

印刷・製本 (株)真興社

 < (株)日本著作出版権管理システム委託出版物 >

小社は捺印または貼付紙をもって定価を変更致しません
乱丁、落丁のものはお買上げ書店または小社にてお取り替え致します

分担研究報告書（卵巣がん）資料3：構造化抄録用文献リスト

- 1) cGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med* 1996 ; 334 : 1-6.
- 2) Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized inter group trial of cisplatin, paclitaxel versus cisplatin, cyclophosphamide in women with advanced epithelial ovarian cancer : three year results. *J Natl Cancer Inst* 2000 ; 92 : 699-708.
- 3) Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era : A metaanalysis. *J Clin Oncol* 2002 ; 20 : 1248-59.
- 4) Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early stage ovarian carcinoma : European Organization for Research and Treatment of Cancer Adjuvant Chemotherapy in Ovarian Neoplasm Trial. *J Natl Cancer Inst* 2003 ; 95 : 113-25.
- 5) Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelde P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage · invasive epithelial ovarian carcinoma. *Lancet* 2001 ; 357 : 176-82.
- 6) Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage · epithelial ovarian carcinoma. *J Clin Oncol* 1996 ; 14 : 2968-75.
- 7) Baiocchi G, Raspagliesi F, Grosso G, Fontanelli R, Cobellis L, di Re E, et al. Early ovarian cancer : Is there a role for systematic pelvic and Para aortic lymphadenectomy? *Int J Gynecol Cancer* 1998 ; 8 : 103-8.
- 8) Kanazawa K, Suzuki T, Takashiki M. The validity and significance of sub stage · c by node involvement in epithelial ovarian cancer : Impact of nodal metastasis on patient survival. *Gynecol Oncol* 1999 ; 73 : 237-41.
- 9) Van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. *N Engl J Med* 1995 ; 332 : 629-34.
- 10) Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to stage I / II patients and superior survival to other stage III patients. *Cancer* 1998 ; 83 : 1555-60.
- 11) Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, Small JM; Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma. *N Engl J Med*. 2004 Dec 9; 351(24): 2489-97.
- 12) De Poncheville L, Perrotin F, Lefrancg T, Lansac J, Body G. Does Para aortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries? *Eur J Cancer* 2001 ; 37 : 210-5.
- 13) Obermair A, Sevelde P. Impact of second look laparotomy and secondary cytoreductive surgery at second look laparotomy in ovarian cancer patients. *Acta Obstet Gynaec Scand* 2001 ; 80 : 432-6.
- 14) Cass I, Li AJ, Runowicz CD, Fields AL, Goldberg GL, Leuchter RS, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. *Gynecol Oncol* 2001 ; 80 : 56-61.
- 15) Tay EH, Grant PT, Gebiski, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial

- ovarian cancer. *Obstet Gynecol* 2002 ; 99 : 1008-13.
- 16) Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. *Gynecol Oncol* 2001 ; 83 : 504-12.
 - 17) Munkarah A, Levenback C, Wolf JK, BodurkaBever D, TortoleroLuna G, Morris RT, et al. Secondary cytoreductive surgery for localized intraabdominal recurrences in epithelial ovarian cancer. *Gynecol Oncol* 2001 ; 81 : 237-41.
 - 18) Nicoletto MO, Tumolo S, Talamini R, Salvagno L, Franceschi S, Visona E, et al. Surgical second look in ovarian cancer : a randomized study in patients with laparoscopic complete remission. *Northeastern Oncology Cooperative Group, Ovarian Cancer Cooperative Group Study. J Clin Oncol* 1997 ; 15 : 994-9.
 - 19) NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. *JAMA*. 1995 ; 273 : 491-7.
 - 20) Zanetta G, Rota S, Chiari S, Bonnazzi C Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma : a prospective study. *J Clin Oncol* 2001 ; 19 : 2658-64.
 - 21) Jobo T, Yonaha H, Iwaya H, Kanai T, Kuramoto H. Conservative surgery for malignant ovarian tumor in women of childbearing age. *Int J Clin Oncol* 2000 ; 5 : 41-7.
 - 22) Morice P, WicartPoque F, Rey A, ElHassan I, Pautier P, Lhomme C, et al. Results of conservative treatment in epithelial ovarian carcinoma. *Cancer* 2001 ; 92 : 2412-8.
 - 23) Sakuragi N, Yamada H, Oikawa M, Okuyama K, Fujino T, Sagawa T, et al. Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0) . *Gynecol Oncol* 2000 ; 79 : 251-5.
 - 24) Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, et al. Chemotherapy in advanced ovarian cancer : four systematic metaanalyses of individual patient data from 37 randomized trials. *Advanced Ovarian Cancer Trialists' Group. Br J Cancer* 1998 ; 78 : 1479-87.
 - 25) Ozols RF, Bundy BN, Greer BE, Fowley JM, ClarkePearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage ovarian cancer : A Gynecologic Oncology Group Study. *J Clin Oncol* 2003 ; 21 : 3194-200.
 - 26) Du Bois A, Lueck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first line treatment of ovarian cancer. *J Natl Cancer Inst* 2003 ; 9 : 1320-9.
 - 27) Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial : two parallel randomized phase III trials of adjuvant chemotherapy in patients with early stage ovarian carcinoma. *J Natl Cancer Inst* 2003 ; 95 : 105-12.
 - 28) Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International collaborative ovarian neoplasm trial 1 : a randomized trial of adjuvant chemotherapy in women with early stage ovarian cancer. *J Natl Cancer Inst* 2003 ; 95 : 125-32.
 - 29) Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. *Lancet* 1992 ; 340 : 329-33.
 - 30) Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. *Scottish gynecology cancer trials group. J Clin Oncol* 1996 ; 14 : 2113-9

- 31) Gore M, Mainwaring P, A' Hern R, MacFarlane V, Slevin M, Harper P, et al. Randomized trial of dose intensity with single agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. *J Clin Oncol* 1998 ; 16 : 2426-34.
- 32) Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB; Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. *J Natl Cancer Inst.* 2004 Nov 17; 96(22): 1682-91.
- 33) Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer : a gynecologic oncology group study. *J Clin Oncol* 2000 ; 18 : 106-15.
- 34) ICON Group, Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer : the ICON3 randomized trial. *Lancet* 2002 ; 360 : 505-15.
- 35) Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ. Use of hematopoietic colony stimulating factors : Comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. *J Clin Oncol* 1999 ; 17 : 3676-81.
- 36) Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony stimulating factors : evidence-based, clinical practice guidelines. *J Clin Oncol* 2000 ; 18 : 3558-85.
- 37) Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics : evidence-based, clinical practice guidelines. *J Clin Oncol* 1999 ; 17 : 2971-94.
- 38) Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIc ovarian carcinoma. *Cancer* 2001 ; 92 : 2585-91.
- 39) Young RC, Brady MF, Nieberg RM, Long HJ, Mayer AR, Lentz SS, et al. Adjuvant treatment for early ovarian cancer : a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin - a Gynecologic Oncology Group study. *J Clin Oncol* 2003 ; 21 : 4350-5.
- 40) Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy : A Southwest Oncology Group and Gynecologic Oncology Group trial. *J Clin Oncol* 2003 ; 21 : 2460-5.
- 41) Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. *N Engl J Med* 1996 ; 335 : 1950-5.
- 42) Markman M, Bundy BN, Alberts DS, Fowler JM, ClarkPearson DL, Carson LF, et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma : an inter group study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. *J Clin Oncol* 2001 ; 19 : 1001-7.
- 43) Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. *Gynecol Oncol* 2002 ; 86 : 34-7.
- 44) Gronlund B, Hogdall C, Hansen HH, Engelholm SA. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. *Gynecol Oncol* 2001 ; 83 : 128-34.

- 45) Rose PG, Fusco N, Fluellen L, Rodrigues M. Second line therapy with paclitaxel and carboplatin for recurrent disease following first line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. *J Clin Oncol* 1998 ; 16 : 1494-7.
- 46) The ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer : the ICON4/AGOVAR2.2 trial. *Lancet* 2003 ; 361 : 2099-106.
- 47) Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, et al. Retrospective analysis of carboplatin and paclitaxel as initial second line therapy for recurrent epithelial ovarian carcinoma : application toward a dynamic disease state model of ovarian cancer. *J Clin Oncol* 2002 ; 20 : 1238-47.
- 48) Donovan KA, Greene PG, Shuster JL, Partridge EE, Tucker DC. Treatment preferences in recurrent ovarian cancer. *Gynecol Oncol* 2002 ; 86 : 200-11.
- 49) Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni, et al. Surgical management of malignant ovarian germ cell tumors : 10 Years' experience of 129 patients. *Obstet Gynecol* 1995 ; 86 : 367-72.
- 50) Williams SD, Birch R, Einhorn L, Irwin L, Greco A, Loehrer PJ. Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. *New Engl J Med* 1987 ; 316 : 1435-40.
- 51) Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin : a trial of the Gynecologic Oncology Group. *J Clin Oncol* 1994 ; 12 : 701-6.
- 52) De Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, et al. Importance of bleomycin in combination chemotherapy for good prognosis testicular nonseminoma : a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. *J Clin Oncol* 1997 ; 15 : 1837-43.
- 53) McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide and cisplatin containing chemotherapy as first line salvage therapy in germ cell tumors : response and survival. *J Clin Oncol* 1997 ; 15 : 2559-63.